AVXL
NASDAQ · Biotechnology
Anavex Life Sciences Corp
$3.34
+0.06 (+1.83%)
Open$3.33
Previous Close$3.28
Day High$3.40
Day Low$3.32
52W High$11.70
52W Low$2.26
Volume—
Avg Volume1.15M
Market Cap312.85M
P/E Ratio—
EPS$-0.46
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+793.7% upside
Current
$3.34
$3.34
Target
$29.85
$29.85
$17.55
$29.85 avg
$40.51
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 62.53M | 56.87M | 56.55M |
| Net Income | 10.24M | 9.50M | 10.72M |
| Profit Margin | 16.4% | 16.7% | 19.0% |
| EBITDA | 18.97M | 15.63M | 16.61M |
| Free Cash Flow | 7.70M | 5.60M | 6.46M |
| Rev Growth | +23.0% | -7.3% | -7.0% |
| Debt/Equity | 0.80 | 0.99 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |